...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)
【24h】

Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)

机译：复发性多发性硬化症患者单核细胞上尿激酶纤溶酶原激活物受体的表达：格拉替雷醋酸酯（共聚物1）的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system in which peripheral blood monocytes play an important role. We have previously reported that patients with chronic progressive MS (CPMS) have significantly increased numbers of circulating monocytes which express the urokinase plasminogen activator receptor (uPAR). In the present study, we examined the expression of uPAR on monocytes in patients with relapsing-remitting multiple sclerosis (RRMS) not currently participating in a clinical trial and in patients with RRMS who were enrolled in a double-blind multicenter clinical trial designed to examine the effect of glatiramer acetate (copolymer 1; Copaxone) on relapsing disease. Patients with CPMS have sustained high levels of circulating uPAR-positive (uPAR+) monocytes. In comparison, patients with RRMS displayed variable levels of circulating uPAR+ monocytes. Mean values for uPAR in patients with RRMS were above those seen for controls but were not as high as those observed for patients with secondary progressive MS. Patients with RRMS in the clinical trial also had variable levels of monocyte uPAR. However, patients in the treatment group displayed lower levels following 2 years of treatment. In both placebo-treated and glatiramer acetate-treated patients, the percentage of circulating uPAR+ monocytes, as well as the density of uPAR expressed per cell (mean linear fluorescence intensity), increased just prior to the onset of a clinically documented exacerbation. Values fell dramatically with the development of clinical symptoms. uPAR levels in all groups correlated with both clinical activity and severity. Results indicate that monocyte activation is impatient in MS and that glatiramer acetate may have a significant effect on monocyte activation in patients with RRMS.
机译：多发性硬化症（MS）是中枢神经系统的一种慢性炎症性疾病，其中外周血单核细胞起着重要的作用。我们以前曾报道过，患有慢性进行性MS（CPMS）的患者表达尿激酶纤溶酶原激活物受体（uPAR）的循环单核细胞数量显着增加。在本研究中，我们检查了uPAR在目前尚未参与临床试验的复发-缓解型多发性硬化症（RRMS）患者和参与双盲多中心临床试验的RRMS患者中单核细胞的表达醋酸格拉替雷（共聚物1; Copaxone）对复发性疾病的影响。 CPMS患者持续存在高水平的循环uPAR阳性（uPAR + ）单核细胞。相比之下，RRMS患者显示出不同水平的循环uPAR + 单核细胞。 RRMS患者的uPAR平均值高于对照组，但不及继发进行性MS患者。在临床试验中患有RRMS的患者单核细胞uPAR水平也有所不同。但是，治疗组的患者在治疗2年后显示出较低的水平。在安慰剂治疗和醋酸格拉替雷治疗的患者中，循环uPAR + 单核细胞的百分比以及每个细胞表达的uPAR密度（平均线性荧光强度）在发病前就增加了临床记录的病情恶化。随着临床症状的发展，价值急剧下降。所有组中的uPAR水平均与临床活动和严重程度相关。结果表明单核细胞激活在MS患者中是不耐烦的，醋酸格拉替雷可能对RRMS患者的单核细胞激活具有重要影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号